Compare VALN & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VALN | GOSS |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 820.0M | 796.2M |
| IPO Year | 2021 | 2019 |
| Metric | VALN | GOSS |
|---|---|---|
| Price | $9.72 | $2.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $15.75 | $8.60 |
| AVG Volume (30 Days) | 25.2K | ★ 4.5M |
| Earning Date | 11-20-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $211,089,992.00 | $44,051,000.00 |
| Revenue This Year | $3.64 | N/A |
| Revenue Next Year | $12.23 | $6.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.48 | N/A |
| 52 Week Low | $4.20 | $0.76 |
| 52 Week High | $12.25 | $3.87 |
| Indicator | VALN | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 65.65 | 32.83 |
| Support Level | $8.77 | $3.04 |
| Resistance Level | $8.98 | $3.87 |
| Average True Range (ATR) | 0.35 | 0.28 |
| MACD | 0.14 | -0.13 |
| Stochastic Oscillator | 91.54 | 0.74 |
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.